Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI AG
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI AG
Subjects
More information
Scope and Contents
Contents
Introduction: The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments. The first PCSK9 antagonists (PCSK9-A), evolocumab and alirocumab, were approved in 2015. Targeting PCSK9 synthesis marked a major advancement in this field, leading to the development of...
Alternative Titles
Full title
Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_163ee951ebe44597bb3b14b6b7c86479
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_163ee951ebe44597bb3b14b6b7c86479
Other Identifiers
ISSN
1424-8247
E-ISSN
1424-8247
DOI
10.3390/ph17101365
